Arcutis Biotherapeutics Inc. (NASDAQ: ARQT) stock soars by 10.38% in current market trading. Arcutis Biotherapeutics has announced that the management is going to participate in a virtual fireside chat during the 2021 Truist Securities Life Sciences Summit, set to happen on 4-5 May 2021. Arcutis Biotherapeutics is a late-stage biopharmaceutical organization dedicated to designing and selling drugs for immune-mediated dermatological disorders and conditions, also known as immuno-dermatology. ARQT is taking advantage of recent advancements in immunology and inflammation to develop distinct treatments against clinically validated targets in order to address ongoing therapeutic problems in severe skin diseases
3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
In a late-breaking oral presentation at the American Academy of Dermatology (AAD) Virtual Meeting Experience (VMX) happened on April 23-25, 2021, ARQT presented the new evidence demonstrating the safety and effectiveness of roflumilast foam for the therapy of scalp and body psoriasis.
Roflumilast Cream and Foam are topical formulations of an extremely active and selective PDE4 inhibitor that are taken once every day. The foam formulation is meant to treat inflammatory dermatoses in hair-bearing areas of the body, such as the scalp, but it can be used elsewhere. The FDA has given its approval to Roflumilast. After 2011, the Food and Drug Administration (FDA) has approved an oral therapy to reduce the incidence of chronic obstructive pulmonary disease (COPD) exacerbations.
The results demonstrate that Roflumilast foam greatly increased both scalp and body psoriasis, according to new results from the late-breaking presentation, with progress as early as two weeks after therapy initiation. Also Roflumilast foam was well tolerated and strengthened scalp and body psoriasis as early as two weeks after therapy began, according to the findings.
During the conference, ARQT will also present data from four additional posters, including one on the protection and effectiveness of roflumilast foam in the prevention of seborrheic dermatitis and three posters on roflumilast cream in mild-to-moderate chronic plaque psoriasis, including its effect on itch and use of steroid-sensitive areas.